Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 211 to 220 of 2451 total matches.
Oliceridine (Olinvyk) - A New Opioid for Severe Pain
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
treatment options are inadequate.1,2
MECHANISM OF ACTION — Binding of an opioid
agonist to μ-opioid ...
Oliceridine (Olinvyk - Trevena), an IV opioid agonist,
has been approved by the FDA for management of
acute pain severe enough to require an opioid and for
which alternative treatment options are inadequate.
In Brief: Fluoroquinolones and Tendon Injuries
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008 (Issue 1300)
Letter
®
On Drugs and Therapeutics
Volume 50 (Issue 1300)
December 1, 2008
www.medicalletter.org ...
The FDA has added a boxed warning to fluoroquinolone package inserts about tendon injuries that may occur as a result of their use. Tendinitis or tendon rupture may occur rarely with systemic use of any fluoroquinolone, either while the drug is being taken or for up to several months afterwards.Fluoroquinolone-related tendon injury is rare; estimates for its incidence in the general population range from 0.14% to 0.4%. The risk is higher for patients >60 years old and for those taking corticosteroids. For patients with organ transplants, the incidence may be as high as 15%.1 A case-control...
Which PPI?
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015 (Issue 1471)
Which PPI? An article published in the New York Times on May 1,
2015 listed the 10 drugs on which ...
An article published in the New York Times on May 1,
2015 listed the 10 drugs on which Medicare Part D
spent the most in 2013. The most costly ($2.53
billion) was the proton pump inhibitor (PPI) Nexium
(esomeprazole magnesium), which has recently become
available generically.
In Brief: Trijardy XR - A New 3-Drug Combination for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
instructions for starting
treatment are complex.
1. Empagliflozin (Jardiance) for diabetes. Med Lett Drugs ...
The FDA has approved Trijardy XR (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose
cotransporter 2 (SGLT2) inhibitor empagliflozin, the
dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, and
extended-release metformin, for oral treatment of type 2
diabetes in adults. Empagliflozin and linagliptin have been
available in a fixed-dose combination as Glyxambi since
2015, and both have been available in 2-drug combinations
with extended-release metformin for years (see Table 1).
Bexagliflozin (Brenzavvy) — A Fifth SGLT2 Inhibitor for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
in the US for this indication
(see Table 4).1
SGLT2 INHIBITORS — SGLT2 inhibitors decrease renal
glucose reabsorption ...
Bexagliflozin (Brenzavvy – TheracosBio), a sodium-glucose
cotransporter 2 (SGLT2) inhibitor, has been
approved by the FDA to improve glycemic control
in adults with type 2 diabetes. It is the fifth SGLT2
inhibitor to be approved in the US for this indication
(see Table 4).
Med Lett Drugs Ther. 2023 Aug 21;65(1683):130-2 doi:10.58347/tml.2023.1683b | Show Introduction Hide Introduction
Aspirin for Prevention of Myocardial Infarction
The Medical Letter on Drugs and Therapeutics • Feb 17, 1995 (Issue 942)
average generic price $ .47
Bayer Aspirin (Sterling Health) 1.77
Low strength 81-mg tablets
average ...
Aspirin is now widely used for antithrombotic prophylaxis in patients who have had angina pectoris or a myocardial infarction and has also been tried in healthy people to prevent myocardial infarction. Recent studies have focused on increasingly lower doses of the drug. The use of aspirin in patients who have had transient ischemic attacks or strokes will not be discussed here.
Belzutifan (Welireg) for Advanced Renal Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
cell carcinoma
(RCC) in adults who received prior treatment with a
programmed death receptor-1 (PD-1 ...
Belzutifan (Welireg – Merck), a first-in-class hypoxia-inducible
factor inhibitor, has been approved by the
FDA for treatment of advanced renal cell carcinoma
(RCC) in adults who received prior treatment with a
programmed death receptor-1 (PD-1) or programmed
death-ligand 1 (PD-L1) inhibitor and a vascular
endothelial growth factor tyrosine kinase inhibitor
(VEGF-TKI). Belzutifan was previously approved for
use in patients with von Hippel-Lindau disease.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):e75-6 doi:10.58347/tml.2024.1701g | Show Introduction Hide Introduction
In Brief: New Recommendations for Use of Metformin in Renal Impairment
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016 (Issue 1493)
was previously contraindicated in women with
a SCr level ≥1.4 mg/dL and in men with a SCr level ≥1.5
mg/dL ...
The FDA has required labeling changes that replace serum creatinine (SCr) with estimated glomerular filtration rate (eGFR) as the parameter used to determine the appropriateness of treatment with the biguanide metformin (Glucophage, and others) in patients with renal impairment. These changes will allow more patients with mild to moderate renal impairment to receive metformin, which is generally the first drug prescribed for treatment of type 2 diabetes.Metformin was previously contraindicated in women with a SCr level ≥1.4 mg/dL and in men with a SCr level ≥1.5 mg/dL, but use of SCr as a...
Lofexidine (Lucemyra) for Opioid Withdrawal
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
.1 It is comparable
in efficacy to the full opioid agonist methadone, but it
is safer and does ...
The FDA has approved lofexidine (Lucemyra – US
WorldMeds/Salix), a centrally acting alpha2 receptor
agonist, to manage withdrawal symptoms in adults
abruptly stopping opioid use. Available in the UK since
1992, lofexidine is the first nonopioid to be approved
in the US for management of opioid withdrawal
symptoms. Clonidine (Catapres, and generics), another
central alpha2 receptor agonist, has been used off-label
for this indication for many years.
Celecoxib Safety Revisited
The Medical Letter on Drugs and Therapeutics • Dec 19, 2016 (Issue 1510)
Celecoxib Safety Revisited
The results of a clinical trial (PRECISION)1 comparing ...
The results of a clinical trial (PRECISION) comparing
the cardiovascular safety of the COX-2 selective
NSAID celecoxib (Celebrex, and generics) with that
of ibuprofen and naproxen, which are nonselective,
have been described in the lay press in terms that may
overestimate the safety of celecoxib.